Skip to content
305-674-7072
info@gibsononcology.com
Icon-facebook
Twitter
Linkedin
Contact Us
Home
Rationale
Lead Program
Additional Program
About Us
Leadership Team and Board of Directors
Scientific Collaborators
Our Science
Publications
Our Pipeline
News and Events
X
Contact Us
Glioblastoma remains a nearly impossible tumor to treat.
The NIH and Gibson Oncology are entering a phase II trial that offers hope for treatment with LMP744
LMP744 has unique combined Top 1 and cMYC activity and easily crosses the blood-brain barrier.
Based on strong pre-clinical evidence of LMP744 activity in GBM, the FDA issued an orphan drug designation (ODD) to Gibson Oncology.
Rationale for LMP744 and LMP400 in Brain Cancer
+ More
Lead Program Glioblastoma
+ More
Additional Programs
+ More
